Grace Therapeutics(GRCE)
$1.86-0.01 (-0.27%)
GRCE
Grace Therapeutics financials statements
$1.86
At close:-0.01 (-0.27%)
Want to see GRCE full AI Analyst Report?
Grace Therapeutics (GRCE) Ratios
1,210 Followers
Grace Therapeutics Ratios
GRCE's free cash flow for Q1 2027 was C$-3.22M. For the 2027 fiscal year, GRCE's free cash flow was increased by C$0.00 and operating cash flow was C$-3.22M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.10 | 11.77 | 14.26 | 8.59 | 13.97 |
| Quick Ratio | 8.10 | 11.77 | 14.26 | 8.59 | 13.97 |
| Cash Ratio | 7.91 | 11.47 | 13.66 | 8.17 | 9.31 |
| Solvency Ratio | -2.82 | -2.53 | -1.11 | -3.79 | -0.48 |
| Operating Cash Flow Ratio | -4.13 | -7.72 | -7.32 | -4.67 | -5.29 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -212.17 | -165.71 |
| Net Current Asset Value | C$ 14.62M | C$ 17.33M | C$ 12.45M | C$ 18.12M | C$ 25.18M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.04 | 1.08 | 1.19 | 1.16 | 1.19 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -114.41 | -141.27 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.07 | 0.05 |
| Net Debt to EBITDA | 1.53 | 0.93 | 1.57 | 1.51 | 1.96 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 82.09% | 74.94% | 87.85% | 81.64% | 93.81% |
| EBT Per EBIT | 85.70% | 76.55% | 129.33% | 99.65% | 67.14% |
| Return on Assets (ROA) | -11.69% | -18.93% | -17.53% | -53.62% | -7.63% |
| Return on Equity (ROE) | -12.20% | -20.46% | -20.82% | -62.44% | -9.07% |
| Return on Capital Employed (ROCE) | -17.17% | -33.90% | -15.80% | -68.89% | -12.44% |
| Return on Invested Capital (ROIC) | -14.10% | -25.41% | -13.88% | -56.18% | -11.66% |
| Return on Tangible Assets | -44.82% | -59.95% | -53.48% | -142.11% | -21.42% |
| Earnings Yield | -10.19% | -49.44% | -57.42% | -189.59% | -53.13% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -33414.09 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 33414.09 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.54 | -1.23 | -1.66 | -2.14 | -2.81 |
| Free Cash Flow Per Share | -0.54 | -1.23 | -1.66 | -2.14 | -2.81 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -560.59 | -936.06 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -560.59 | -936.06 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -32.81 | -58.42 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -11.60% | -54.08% | -55.20% | -71.18% | -93.25% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.85 | -2.02 | -1.74 | -0.53 | -1.88 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.20 | 0.41 | 0.36 | 0.33 | 0.17 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.62 | -1.85 | -1.81 | -1.40 | -1.07 |
| Price-to-Operating Cash Flow Ratio | -8.62 | -1.85 | -1.81 | -1.41 | -1.07 |
| Price-to-Earnings Growth (PEG) Ratio | 0.17 | 0.05 | 0.02 | -0.00 | 0.02 |
| Enterprise Value Multiple | -5.37 | -0.23 | 0.04 | 0.28 | 0.75 |
| Enterprise Value | 59.47M | 5.43M | -622.64K | -5.01M | -11.56M |
| EV to EBITDA | -5.37 | -0.23 | 0.04 | 0.28 | 0.75 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -6.71 | -0.36 | 0.05 | 0.31 | 0.67 |
| EV to Operating Cash Flow | -6.71 | -0.36 | 0.05 | 0.31 | 0.67 |
| Tangible Book Value Per Share | 0.89 | 1.43 | 1.68 | 2.51 | 4.15 |
| Shareholders’ Equity Per Share | 3.87 | 5.51 | 8.30 | 9.14 | 17.63 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.18 | 0.25 | 0.12 | 0.18 | 0.06 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.47 | -1.13 | -1.73 | -5.71 | -1.60 |
| Tax Burden | 0.82 | 0.75 | 0.88 | 0.82 | 0.94 |
| Interest Burden | 0.86 | 0.77 | 1.00 | 2.85 | 0.68 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.14 | 1.56 | 0.96 | 0.38 | 1.76 |
Currency in CAD
